IL109059A - תכשירי רוקחות לטיפול בבחילה ובהקאות שלאחר ניתוח המכילים גרניסטרון - Google Patents

תכשירי רוקחות לטיפול בבחילה ובהקאות שלאחר ניתוח המכילים גרניסטרון

Info

Publication number: IL109059A
Authority: IL; Israel
Prior art keywords: placebo; vomiting; granisetron; nausea; treatment
Prior art date: 1993-03-18

Application number

IL10905994A

Other languages

English (en)

Other versions

IL109059A0 (en

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-18

Filing date

1994-03-21

Publication date

1996-11-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10732290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL109059(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-03-21 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1994-11-28 Publication of IL109059A0 publication Critical patent/IL109059A0/xx

1996-11-14 Publication of IL109059A publication Critical patent/IL109059A/he

Links

MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 title claims description 23
229960003727 granisetron Drugs 0.000 title claims description 23
208000031649 Postoperative Nausea and Vomiting Diseases 0.000 title claims description 18
238000011282 treatment Methods 0.000 title claims description 16
239000008194 pharmaceutical composition Substances 0.000 title claims description 5
239000000203 mixture Substances 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 1
229940068196 placebo Drugs 0.000 description 42
239000000902 placebo Substances 0.000 description 42
206010047700 Vomiting Diseases 0.000 description 21
230000008673 vomiting Effects 0.000 description 19
206010028813 Nausea Diseases 0.000 description 14
230000008693 nausea Effects 0.000 description 14
238000009826 distribution Methods 0.000 description 8
230000004083 survival effect Effects 0.000 description 8
238000000034 method Methods 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
230000003474 anti-emetic effect Effects 0.000 description 6
239000002111 antiemetic agent Substances 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002265 prevention Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000001949 anaesthesia Methods 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
210000004916 vomit Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010038776 Retching Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
238000002192 cholecystectomy Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
-1 colourants Substances 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
230000036407 pain Effects 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
229940127558 rescue medication Drugs 0.000 description 1
238000009118 salvage therapy Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hospice & Palliative Care (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Treatment Of Sludge (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IL10905994A 1993-03-18 1994-03-21 תכשירי רוקחות לטיפול בבחילה ובהקאות שלאחר ניתוח המכילים גרניסטרון IL109059A (he)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB939305593A GB9305593D0 (en)	1993-03-18	1993-03-18	Pharmaceuticals

Publications (2)

Publication Number	Publication Date
IL109059A0 IL109059A0 (en)	1994-11-28
IL109059A true IL109059A (he)	1996-11-14

Family

ID=10732290

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10905994A IL109059A (he)	1993-03-18	1994-03-21	תכשירי רוקחות לטיפול בבחילה ובהקאות שלאחר ניתוח המכילים גרניסטרון

Country Status (20)

Country	Link
US (1)	US5952340A (he)
EP (1)	EP0689437B1 (he)
JP (2)	JP3792251B2 (he)
KR (1)	KR100315606B1 (he)
CN (1)	CN1085079C (he)
AP (1)	AP511A (he)
AT (1)	ATE230596T1 (he)
AU (1)	AU676032B2 (he)
CA (1)	CA2158354C (he)
CY (1)	CY2427B1 (he)
DE (1)	DE69431986T2 (he)
DK (1)	DK0689437T3 (he)
ES (1)	ES2188611T3 (he)
GB (1)	GB9305593D0 (he)
HU (1)	HU214629B (he)
IL (1)	IL109059A (he)
SG (1)	SG46724A1 (he)
TW (1)	TW312622B (he)
WO (1)	WO1994021257A1 (he)
ZA (1)	ZA941844B (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9412995D0 (en) *	1994-06-28	1994-10-26	Prendergast Kenneth F	Safety enhancing pharmaceutical compositions of an active indazole
WO2003100091A1 (en) *	2002-05-24	2003-12-04	Epidauros Biotechnologie Ag	Means and methods for improved treatment using 'setrones'
SE0203410D0 (sv) *	2002-11-18	2002-11-18	Astrazeneca Ab	New use
JO2735B1 (en) *	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formulations of palonosetron
MY143789A (en)	2003-02-18	2011-07-15	Helsinn Healthcare Sa	Use of palonosetron treating post- operative nausea and vomiting
GB0328186D0 (en) *	2003-12-05	2004-01-07	West Pharm Serv Drug Res Ltd	Intranasal compositions
JP6081102B2 (ja) *	2012-08-10	2017-02-15	テルモ株式会社	安定なグラニセトロン含有水性製剤
GB201618425D0 (en) *	2016-11-01	2016-12-14	Acacia Pharma Ltd	method
JP2017077484A (ja) *	2016-11-30	2017-04-27	テルモ株式会社	安定なグラニセトロン含有水性製剤の包装体
GB201702250D0 (en)	2017-02-10	2017-03-29	Acacia Pharma Ltd	Method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3650772T2 (de) *	1985-04-27	2003-04-03	F. Hoffmann-La Roche Ag, Basel	Derivate von Indazole-3-carboxamide und -3-carboxylsäure
GB8525913D0 (en) *	1985-10-21	1985-11-27	Beecham Group Plc	Compounds
GB8928837D0 (en) *	1989-12-21	1990-02-28	Beecham Group Plc	Pharmaceuticals
US5225407A (en) *	1990-02-22	1993-07-06	Glaxo Group Limited	5-HT3 receptor antagonists for the treatment of autism
DE69231395T3 (de) *	1991-09-20	2005-07-21	Glaxo Group Ltd., Greenford	Neue medizinische Indikation für Tachykinin-Antagonisten

1993
- 1993-03-18 GB GB939305593A patent/GB9305593D0/en active Pending
1994
- 1994-03-15 JP JP52064194A patent/JP3792251B2/ja not_active Expired - Lifetime
- 1994-03-15 SG SG1996009426A patent/SG46724A1/en unknown
- 1994-03-15 AU AU63774/94A patent/AU676032B2/en not_active Expired
- 1994-03-15 EP EP94911178A patent/EP0689437B1/en not_active Revoked
- 1994-03-15 CA CA002158354A patent/CA2158354C/en not_active Expired - Lifetime
- 1994-03-15 HU HU9502692A patent/HU214629B/hu unknown
- 1994-03-15 US US08/525,521 patent/US5952340A/en not_active Expired - Lifetime
- 1994-03-15 DE DE69431986T patent/DE69431986T2/de not_active Revoked
- 1994-03-15 ES ES94911178T patent/ES2188611T3/es not_active Expired - Lifetime
- 1994-03-15 WO PCT/EP1994/000820 patent/WO1994021257A1/en not_active Ceased
- 1994-03-15 KR KR1019950703945A patent/KR100315606B1/ko not_active Expired - Lifetime
- 1994-03-15 DK DK94911178T patent/DK0689437T3/da active
- 1994-03-15 AT AT94911178T patent/ATE230596T1/de not_active IP Right Cessation
- 1994-03-16 ZA ZA941844A patent/ZA941844B/xx unknown
- 1994-03-16 AP APAP/P/1994/000626A patent/AP511A/en active
- 1994-03-21 IL IL10905994A patent/IL109059A/he not_active IP Right Cessation
- 1994-04-06 TW TW083102963A patent/TW312622B/zh not_active IP Right Cessation
- 1994-09-29 CN CN94192028A patent/CN1085079C/zh not_active Expired - Lifetime
2004
- 2004-02-25 CY CY0400013A patent/CY2427B1/xx unknown
2005
- 2005-12-13 JP JP2005359022A patent/JP2006083190A/ja active Pending

Also Published As

Publication number	Publication date
AP511A (en)	1996-07-26
JPH08507774A (ja)	1996-08-20
ES2188611T3 (es)	2003-07-01
TW312622B (he)	1997-08-11
HU214629B (hu)	1998-04-28
EP0689437B1 (en)	2003-01-08
HU9502692D0 (en)	1995-11-28
ZA941844B (en)	1995-09-18
AU6377494A (en)	1994-10-11
CA2158354A1 (en)	1994-09-29
DE69431986D1 (de)	2003-02-13
DK0689437T3 (da)	2003-04-28
CY2427B1 (en)	2004-11-12
JP2006083190A (ja)	2006-03-30
HUT73502A (en)	1996-08-28
CN1085079C (zh)	2002-05-22
SG46724A1 (en)	1998-02-20
IL109059A0 (en)	1994-11-28
EP0689437A1 (en)	1996-01-03
ATE230596T1 (de)	2003-01-15
HK1012237A1 (en)	1999-07-30
AU676032B2 (en)	1997-02-27
GB9305593D0 (en)	1993-05-05
DE69431986T2 (de)	2003-11-06
JP3792251B2 (ja)	2006-07-05
CN1122570A (zh)	1996-05-15
KR100315606B1 (ko)	2002-04-24
AP9400626A0 (en)	1994-04-30
US5952340A (en)	1999-09-14
CA2158354C (en)	2004-07-13
WO1994021257A1 (en)	1994-09-29

Legal Events

Date	Code	Title
1998-02-22	CB	Opposition filed against grant of patent
2002-02-10	HP	Change in proprietorship
2005-02-20	KB	Patent renewed
2008-04-13	KB	Patent renewed
2012-03-29	KB	Patent renewed
2014-11-30	EXP	Patent expired

Publication	Publication Date	Title
US4446140A (en)	1984-05-01	Method and composition for treating mouth pain
DE60009697T2 (de)	2005-04-14	Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
US4804669A (en)	1989-02-14	Treatment of pain with a piperidine
EP0689437B1 (en)	2003-01-08	Use of granisetron for the treatment of post-operative nausea and vomiting
NZ504656A (en)	2002-02-01	Substituted aminomethyl-chromans are used for the regenerative treatment of neurological conditions which are the sequelae of damage due to surgical intervention, exposure to toxic agents, infections, tumours, and other diseases and conditions
JPH0320222A (ja)	1991-01-29	脳内虚血症治療剤
EP0081823A1 (en)	1983-06-22	Composition for reducing menstrual pain
US20060160887A1 (en)	2006-07-20	Medicinal composition
HK1012237B (en)	2003-10-03	Use of granisetron for the treatment of post-operative nausea and vomiting
US5876751A (en)	1999-03-02	Antispasmodic and antinflammatory composition and a process for the manufacture thereof
US9393236B2 (en)	2016-07-19	Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas
CN1146420C (zh)	2004-04-21	[R－（Z）]-a-（甲氧基亚氨基）-a-（1－氮杂双环[2.2.2]辛－3－基）乙腈在制备治疗精神病的药物中的应用
WO1998038997A1 (en)	1998-09-11	Use of levobupivacaine in combination with opiods or alfa2-agonists for providing anaesthesia or analgesia
US6162792A (en)	2000-12-19	Use of spiramycin for treating gastrointestinal disorders caused by H. pylori
GB2189703A (en)	1987-11-04	Vinpocetine
EP0868915A1 (en)	1998-10-07	An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium
WO2000056336A2 (en)	2000-09-28	Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
WO1997023477A1 (en)	1997-07-03	Dibenzothiepin derivatives and pharmaceutical compositions
EP0723448A1 (en)	1996-07-31	Use of peniclorin for the treatment of posttherapeutic neuralgia
JPH0132804B2 (he)	1989-07-10
MXPA01000466A (en)	2001-09-07	Method of treatment